We give you a written timeline estimate for your case before you commit.Get my quote
Is Fayuvi available in Kuwait? How families get Fayuvi (rebisufligene etisparvovec-hopf)
A plain answer for families in Kuwait, checked against FDA, manufacturer and regulator sources.
Reviewed by the Reserve Meds clinical operations team on 13 October 2026.
Is Fayuvi available in Kuwait?
Fayuvi (rebisufligene etisparvovec-hopf) is an FDA-approved one-time AAV9 gene therapy for Sanfilippo syndrome type A (MPS IIIA) in children. As of 13 October 2026, we found no public record that Fayuvi is registered by MOH in Kuwait. Fayuvi is given only at specialized treatment centers, so for most families in Kuwait the realistic route is treatment at a qualified center abroad, after a referral from the treating specialist. If a hospital in Kuwait wants to give it locally, the manufacturer must agree to supply that hospital and the Kuwait Ministry of Health (MOH) must approve the import. Plan in months, not weeks (our planning estimate, not a promise). Reserve Meds helps organize the referral and logistics. We do not prescribe.
- Registration in Kuwait: not found in public sources as of 13 October 2026. Your hospital confirms before filing.
- Legal route: Treatment at a qualified center abroad, or a hospital import request if the manufacturer agrees.
- Who applies: your treating specialist refers the patient to a qualified center; a hospital in Kuwait applies to MOH only if the manufacturer agrees to supply it.
- Timeline: several months (not a promise).
- Medicine price: quote on request. Every case gets a written custom quote before you commit.
What Fayuvi is
Fayuvi (rebisufligene etisparvovec-hopf) is made by Ultragenyx Pharmaceutical. The US FDA approved it on 17 September 2026 for the neurologic manifestations of mucopolysaccharidosis type IIIA (MPS IIIA, Sanfilippo syndrome type A) in pediatric patients with preserved neurodevelopmental function. It is given as a single intravenous (IV) infusion, given in a specialized healthcare setting.
It is the first FDA-approved treatment for Sanfilippo syndrome type A. Ultragenyx said the FDA granted standard (full) approval. The treating team will explain the monitoring needed before and after a gene therapy infusion.
At approval, Fayuvi was approved only in the United States. Ultragenyx announced in October 2026 that it had submitted a marketing application to the European Medicines Agency.
The legal route in Kuwait
Fayuvi is a one-time infusion given in a specialized healthcare setting. Children must still have preserved neurodevelopmental function, so the treating team will assess the child first. Timing matters for this disease.
For a family in Kuwait, that leaves two realistic routes. First, treatment at a qualified center abroad, after your specialist refers you and the center accepts the patient. Second, a hospital in Kuwait asks the manufacturer, Ultragenyx Pharmaceutical, whether it will supply that hospital. If the manufacturer agrees, the hospital still needs import approval from the Kuwait Ministry of Health (MOH). We cannot promise that a manufacturer will agree.
How a hospital import request works in Kuwait, if it is ever needed:
In Kuwait, the Ministry of Health (MOH) controls which medicines are registered and imported.
Under Ministerial Resolution No. 100 of 2023, a non-registered medicine can be brought in when it is used to diagnose, treat or prevent disease, it is already registered with an overseas regulator such as the US FDA, and no alternative is available in Kuwait. The request is made through MOH and follows the rules of its registration and control department. Your treating hospital starts this process.
MOH has worked with manufacturers to bring in new specialty therapies before. For example, MOH, AAW and Roche announced the registration and introduction of the Duchenne gene therapy Elevidys in Kuwait in June 2024.
Who does what
- Your treating specialist decides whether Fayuvi is right for the patient and writes the letter and prescription.
- The hospital refers the patient, or files a local import request if that becomes possible.
- The Kuwait Ministry of Health (MOH) decides whether to approve an import of an unregistered medicine.
- Ultragenyx Pharmaceutical makes Fayuvi and decides where it can be supplied.
- Reserve Meds can help organize records and logistics, and keeps your family updated. We do not give medical advice.
Documents you will usually need
- A referral letter from the treating specialist: diagnosis, test results and why this treatment is being considered
- Genetic or laboratory reports that confirm the diagnosis, translated into English where needed
- Recent clinic notes, imaging and a list of past treatments
- Passport and travel documents, if treatment happens abroad
- A funding plan: personal funds, insurer approval, or a government treatment-abroad decision
Timeline, step by step
- Referral. Your specialist prepares a referral letter and the medical records.
- Center review. A qualified treatment center reviews the records and decides whether the patient is eligible.
- Funding and travel. The family confirms funding and plans travel and accommodation.
- Preparation. The center runs tests and, for some products, collects cells or tissue to make the treatment.
- Treatment and follow-up. The patient is treated and then followed up by the center and the home specialist.
The overall time is our planning estimate, not a promise. The regulator and the manufacturer set their own timelines.
What Fayuvi costs
Medicine price: quote on request. Your total cost depends on the dose, shipping, import steps and coordination. Your coordination fee is quoted in writing for your case before you commit. No hidden charges.
How Reserve Meds helps
Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We help your doctor and hospital prepare the file, arrange US supply and shipping once approval is in place, and keep your family updated. We coordinate access to FDA-approved medicines only. We do not prescribe, and we do not decide what the regulator approves.
Ask about Fayuvi in Kuwait
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
Frequently asked questions
Is Fayuvi approved in Kuwait?
As of 13 October 2026, we found no public record that Fayuvi is registered by MOH in Kuwait. At approval, Fayuvi was approved only in the United States. Ultragenyx announced in October 2026 that it had submitted a marketing application to the European Medicines Agency. Ask your hospital pharmacy to confirm the current status with the Ministry of Health's drug registration and control department before anything is filed.
Who applies for permission to use Fayuvi in Kuwait?
For treatment abroad, your specialist refers the patient to a qualified center. For a local hospital import, the hospital applies to the Kuwait Ministry of Health (MOH), and the manufacturer must agree to supply.
How long does it take to get Fayuvi in Kuwait?
Plan in months, not weeks. The center must review the records, accept the patient and prepare the treatment. This is our planning estimate, not a promise.
How much does Fayuvi cost?
Medicine price: quote on request. Your total cost, including shipping, import steps and coordination, is quoted in writing for your case before you commit. No hidden charges.
Can Fayuvi be given in Kuwait instead of abroad?
Only if the manufacturer agrees to supply a hospital in Kuwait and MOH approves the import. We will tell you honestly if that is not possible today.
Sources
Checked on 13 October 2026. Regulator rules change. Your hospital pharmacy confirms the current procedure before filing.
- FDA: FAYUVI (rebisufligene etisparvovec-hopf) product page, approved 17 Sep 2026
- Ultragenyx: approval of FAYUVI gene therapy, 17 Sep 2026 (press release via Finviz)
- WebMD: FDA approves Fayuvi (single IV infusion in a specialized healthcare setting)
- Al Tamimi & Co: Kuwait Ministry of Health restrictions on the supply of non-registered medical products (Resolution No. 100 of 2023)
- AAW: with the Ministry of Health, AAW and Roche introduce Elevidys to Kuwait, 23 Jun 2024